Sentinel Surveillance of Influenza-Like Illness in Two Hospitals in Maracay, Venezuela: 2006–2010

Guillermo Comach1*, Nimfa Teneza-Mora2, Tadeusz J. Kochel2,3, Carlos Espino1, Gloria Sierra1, Daria E. Camacho1, V. Alberto Laguna-Torres3, Josefina Garcia3, Gloria Chauca3, Maria E. Gamero3, Merly Sovero3, Slave Bordones4, Iris Villalobos5, Angel Melchor6, Eric S. Halsey3

1 Laboratorio Regional de Diagnostico e Investigacion del Dengue y otras Enfermedades Virales (LARDIDEV), Instituto de Investigaciones Biomedicas de la Universidad de Carabobo (BIOMED-UC), Maracay, Venezuela, 2 Naval Medical Research Center, Silver Spring, Maryland, United States of America, 3 U.S. Naval Medical Research Unit Six (NAMRU-6), Lima, Peru, 4 Hospital José María Caraballo Tosta, Instituto Venezolano de los Seguros Sociales, Maracay, Venezuela, 5 Hospital Central de Maracay, Corporación de Salud de Aragua (CORPSALUD ARAGUA), Maracay, Venezuela, 6 Dirección de Epidemiología, Corporación de Salud de Aragua (CORPSALUD ARAGUA), Maracay, Venezuela

Abstract

Background: Limited information exists on the epidemiology of acute febrile respiratory illnesses in tropical South American countries such as Venezuela. The objective of the present study was to examine the epidemiology of influenza-like illness (ILI) in two hospitals in Maracay, Venezuela.

Methodology/Principal Findings: We performed a prospective surveillance study of persons with ILI who presented for care at two hospitals in Maracay, Venezuela, from October 2006 to December 2010. A respiratory specimen and clinical information were obtained from each participant. Viral isolation and identification with immunofluorescent antibodies and molecular methods were employed to detect respiratory viruses such as adenovirus, influenza A and B, parainfluenza, and respiratory syncytial virus, among others. There were 916 participants in the study (median age: 17 years; range: 1 month – 86 years). Viruses were identified in 143 (15.6%) subjects, and one participant was found to have a co-infection with more than one virus. Influenza viruses, including pandemic H1N1 2009, were the most frequently detected pathogens, accounting for 67.4% (97/144) of the viruses detected. Adenovirus (15/144), parainfluenza virus (13/144), and respiratory syncytial virus (11/144) were also important causes of ILI in this study. Pandemic H1N1 2009 virus became the most commonly isolated influenza virus during its initial appearance in 2009. Two waves of the pandemic were observed: the first which peaked in August 2009 and the second – higher than the preceding – that peaked in October 2009. In 2010, influenza A/H3N2 re-emerged as the most predominant respiratory virus detected.

Conclusions/Significance: Influenza viruses were the most commonly detected viral organisms among patients with acute febrile respiratory illnesses presenting at two hospitals in Maracay, Venezuela. Pandemic H1N1 2009 influenza virus did not completely replace other circulating influenza viruses during its initial appearance in 2009. Seasonal influenza A/H3N2 was the most common influenza virus in the post-pandemic phase.

Citation: Comach G, Teneza-Mora N, Kochel TJ, Espino C, Sierra G, et al. (2012) Sentinel Surveillance of Influenza-Like Illness in Two Hospitals in Maracay, Venezuela: 2006–2010. PLoS ONE 7(9): e44511. doi:10.1371/journal.pone.0044511

Editor: Cécile Viboud, National Institutes of Health, United States of America

Received April 14, 2012; Accepted August 3, 2012; Published September 11, 2012

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Funding: This study was funded by the United States Department of Defense, Global Emerging Infections Surveillance and Response System, a Division of the Armed Forces Health Surveillance Center, WORK UNIT NUMBER: 847705.82000.25GB.B0016. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: gcomach@yahoo.com

Introduction

Acute respiratory infection (ARI) remains a leading cause of global burden of disease, and is the second most common cause of illness worldwide, with an annual global incidence exceeding 400 million [1–3]. A prerequisite of public health planning to reduce global disease burden from ARI is to examine data on its epidemiology in order to better define environmental factors as well as target populations for preventive interventions [4]. Respiratory viruses are predominant causes of ARIs, and the epidemiology of acute viral respiratory illnesses in developed countries with temperate climates has been well-characterized [5–7]. In countries such as the United States, children have been shown to carry a large burden of viral respiratory diseases [5]. Recent prospective studies, which utilized more sensitive methods for detecting respiratory viruses such as multiplex polymerase chain reaction (PCR), have similarly demonstrated that the highest rates of viral respiratory infection occur among children and the frequency of infection tends to decrease with age due to increasing acquired immunity [8]. Respiratory syncytial virus (RSV), influenza virus, parainfluenza virus, and rhinovirus have long been identified as common causes of ARI [9]. Recent improvements in molecular detection techniques have allowed the identification of multiple new respiratory viruses such as human metapneumovirus (hMPV), human bocavirus (HBoV) and human coronavirus NL63.
Influenza viruses are among the most impactful acute respiratory pathogens in terms of morbidity and mortality. Despite developed public health intervention programs, the estimated annual average number of influenza-related hospitalizations in the United States exceeds 200,000, and 36,000 deaths are attributable to influenza infections yearly [10,11]. Information on the contribution of influenza viruses to the global burden of disease due to acute respiratory illness is incomplete. Data on the epidemiology of influenza viruses in developed countries are derived from multiple sources to include laboratory-based surveillance, sentinel surveillance, as well as hospitalization and outpatient records. In developing countries, where resources are sparse, sentinel surveillance methods may be more readily accessible and more cost-effective than laboratory-based or population-based surveillance for determining the viral etiology of influenza-like illness (ILI) in these regions. Better identification of the viral causes of ILI will enable clinicians in resource-limited settings to appropriately treat and manage patients; more importantly, it will allow public health officials to formulate more effective prevention and control strategies, including monitoring of influenza vaccine efficacy in their communities [12].

Studies on the epidemiology of ILI in the tropical South and Central American countries of Peru, Brazil, Ecuador, Nicaragua, Honduras, and El Salvador have been published [13–16]. A prospective study of adults with ILI in Sao Paulo, Brazil, revealed that while influenza viruses were the predominant cause of ILI, rhinoviruses and other respiratory viruses were detected in 19.6% and 13.7% of subjects, respectively [14]. This observation illustrated that a significant proportion of patients who are clinically diagnosed with influenza virus infection may have symptoms indistinguishable from other respiratory viruses. In a prospective study of ILI in Ecuador, the regional distribution of influenza virus infections varied; a higher detection rate of influenza A occurred in Quito, located in the highlands where the level of absolute humidity is lower, whereas influenza A detection rate was lower in the coastal city of Guayaquil, which has a more humid tropical climate [15]. Additionally, an expanded sentinel surveillance of ILI conducted at 31 health centers and hospitals located in 13 Peruvian cities showed that the distribution of ILI-causing viruses varied by region [13]. These studies illustrate the importance of conducting baseline and continuing ILI surveillance in other countries of Central and South America because ILI can be caused by pathogens other than influenza viruses. The distribution of respiratory infections may vary within the region or within a particular country, depending on climate and topography.

In Venezuela, ARI is the primary cause of weekly notifiable diseases registered by the National Epidemiological Surveillance System (NESS) [17]. Nonetheless, very low numbers of respiratory samples were collected (16,664 from 2006 to 2010) and even lower numbers (3,167) were confirmed by the National System for Virological Surveillance of ARI [17–21]. Furthermore, the epidemiology, clinical characteristics, and viral causes of ILI have been poorly characterized in Venezuela; to our knowledge, only one longitudinal study, carried out during a limited period of time (February 2005–July 2006) and with a low number of patients (n = 102) with ARI, has been published [22]. The objective of this paper is to describe the epidemiology of ILI using data from a sentinel surveillance system at two major hospitals in Maracay, Venezuela.

## Results

### General Findings

A total of 916 subjects participated in this study. Six hundred and thirty-seven (69.5%) were recruited at the Hospital Central de Maracay (HCM). There was a slightly larger proportion of females compared with males who enrolled in the study (55.2% vs 44.8%), and the gender distributions at the two sites were similar. Subject ages ranged from 1 month to 86 years with a mean age of 19.2 years (S.D. = 14.3 years) and a median of 17 years. A significant percentage of the subjects (17.6%) were under 5 years of age, while less than 1.0% were 60 years or older. The 15–29 year old group was the most predominant group comprising 32.8% of the study population, followed by the 5–14 year old age group (27.2%). The subjects who presented to HCM were significantly older (mean age = 21.2 years; S.D. = 13.2 years) compared with those who were seen at the Hospital del Instituto Venezolano de los Seguros Sociales Jose Maria Carabano Tosta (IVSS-JMCT) (mean age = 14.4 years; S.D. = 15.6 years). A large proportion (37.8%) of the subjects at HCM belonged to the 15–29 age group, while nearly half of the patients (42.3%) seen at IVSS-JMCT were younger than 5 years old. Approximately 5% of the subjects reported having received influenza vaccination within the last year. A small percentage of patients (2.0%) received antibiotic treatment for their acute respiratory illness prior to enrollment in the study. No hospitalized cases with ILI were recruited in this study; only outpatient subjects participated. Demographic information is summarized in Table 1.

### Laboratory Results

Among the 916 patient samples obtained from the sentinel surveillance, at least one viral organism was detected by viral isolation and/or reverse transcriptase-polymerase chain reaction (RT-PCR) in 143 (15.6%) subjects (Table 2). Only one participant with a co-infection was observed. Influenza viruses were the most frequently detected organisms in this passive surveillance, consisting of 67.4% (97/144) of the viruses detected by viral isolation and/or RT-PCR. Of the 916 samples collected, 78 (8.5%) were positive for influenza A viruses and 19 (2.1%) for influenza B viruses by viral isolation and/or RT-PCR. In addition, non-influenza viruses were detected only by virus isolation; they were: adenovirus (1.6%), parainfluenza virus (1.4%), RSV (1.2%), and other viruses (0.8%), which included HBoV (0.1%), enterovirus (0.2%), hMPV (0.1%), rhinovirus (0.1%), and herpes simplex virus (HSV, 0.2%). The only co-infection was observed in a 22 month old toddler in whom adenovirus and HSV were isolated.

The virus etiology and detection rates varied with age (Table 2). The most commonly detected viral pathogens in the 0–4 year old group were influenza A (11.1%) and adenoviruses (5.6%). Influenza A and B were the most commonly detected viruses in the school-age group (5–14 year old: 6.8% and 4.0%, respectively) and the late adolescent and young adult group (15–29 year-old: 9.7% and 1.7%, respectively). Influenza A was the only detectable virus among patients who were 60 years or older.

Of the 78 influenza A cases, H3 subtype was detected in 33, and was observed in all the age groups but in subjects aged 43–59 year old (Table 2). Six cases had the H1 subtype (non-pandemic), and 16 influenza A viruses were isolated but not subtyped by one-step RT-PCR; of the latter, 11 can be classified as seasonal because they were isolated from patients samples collected before the start of the H1N1 pandemic outbreak of 2009. Twenty-one cases of pandemic H1N1 2009 influenza virus (pH1N1) infections were identified in this sentinel surveillance; thirteen occurred in the 15–
29 year old group. There were no cases of pH1N1 infections among adults 45 years old or higher.

Phylogenetic Analysis

Genetic analysis based on partial hemagglutinin gene sequences (approximately 900 bp) of 27 influenza isolates is shown in Figure 1 (See Material and Methods for GenBank accession numbers). This analysis shows that the circulating seasonal A/H1N1 strains in Venezuela (Figure 1A) were similar to the ones previously described in Central and South America [15,16] and all of these samples can be grouped with the A/Brisbane/56/07 like 2008–2009 genotype. The pH1N1 samples were part of only one cluster similar to previously reported strains in Latin America [23]. Influenza A/H3N2 samples possessed more genetic variability (Figure 1B); isolates from 2007 revealed two genotypes, A/Brisbane/10/07-like and A/California/7/04-like, while the more recent isolates were closer to the A/Perth/16/09-like genotype. Finally, in Figure 1C, the genetic analysis for influenza B isolates disclosed the presence of two different genotypes, B/Florida4/06-like and B/Malaysia/2506/07-like, in agreement to what was previously found in the region [13,16].

Temporal Distribution

Figures 2 and 3 illustrate the temporal distribution of ILI and the viral etiology of ILI, respectively, from October 2006 through December 2010. ILI was observed throughout the year with irregular peak activity occurring once or twice annually during the months of June 2007, January 2008, January and October 2009, and June 2010 (Figure 2). The pattern of influenza A occurrence was variable from year to year (Figure 3). Influenza A virus was not detected during every month of every year and was observed during 3–6 month periods in 2007, 2009, and 2010 (4, 6, and 3 months, respectively). Lower influenza A activity was observed in 2008, with detection only during the months of January, March, and September. The occurrence of peak ILI activity correlated with the detection of influenza A virus in the subjects’ respiratory samples during those months (see Figures 2 and 3). Peak influenza B virus activity was detected in January 2008 and December 2010. Adenovirus was detected more frequently from December to April. RSV infection occurred more frequently from June to November. Parainfluenza viruses were detectable throughout the year but without distinct seasonality.

The passive surveillance illustrated the impact of pH1N1 on the distribution of respiratory viruses associated with ILI in 2009 (Figure 3). During the ILI peaks from 2006–2010, the percentage of ILI cases attributable to influenza viruses ranged from 10% to 44%. The first cases of pH1N1 in this surveillance system were detected in July 2009, three months after the swine origin influenza outbreak began in Mexico [24]. During the first wave in July 2009, the monthly virus detection rate rose to 33%, and 57% (4/7) of all the viruses detected were of the pandemic strain. The first wave simulated a typical ILI peak activity similar to those observed in other years. However, during the larger second wave in October 2009, the virus positivity rate exceeded 40%, and the pandemic strain was
identified in greater than 73% (11/15) of the viruses detected. Figure 3 demonstrates that pH1N1 did not completely replace seasonal influenza A viruses. The peak pandemic activity in October 2009 was followed by a rapid decline in the rate of seasonal influenza A viruses. The peak pandemic activity in October 2009 was followed by a rapid decline in the rate of seasonal influenza A viruses. The peak pandemic activity in October 2009 was followed by a rapid decline in the rate of seasonal influenza A viruses. The peak pandemic activity in October 2009 was followed by a rapid decline in the rate of seasonal influenza A viruses. The peak pandemic activity in October 2009 was followed by a rapid decline in the rate of seasonal influenza A viruses. The peak pandemic activity in October 2009 was followed by a rapid decline in the rate of seasonal influenza A viruses. The peak pandemic activity in October 2009 was followed by a rapid decline in the rate of seasonal influenza A viruses. The peak pandemic activity in October 2009 was followed by a rapid decline in the rate of seasonal influenza A viruses.

## Clinical Manifestations

The clinical features of subjects in our surveillance are summarized in Table 3. Compared with those whose respiratory secretions tested negative, subjects in which virus was identified were more likely to have sore throat, headache, pharyngeal congestion, and ear pain. There were no significant differences in the symptoms of individuals who had seasonal influenza A when compared with those who suffered from pH1N1 influenza, except that a higher proportion of the latter subjects had expectoration, myalgias, and lymphadenopathy. The symptoms of influenza A (either seasonal or pandemic) and influenza B were clinically indistinguishable. When compared with patients who had ILI due to other viruses, a higher percentage of those with confirmed influenza virus infection experienced sore throat, myalgias, and headache.

### Discussion

There is scarce information about the epidemiology of acute febrile respiratory illness in Venezuela and, to our knowledge, only one longitudinal study has been published [22]. This investigation, however, was limited to few number of subjects (n = 102) recruited during a short period of time (17 months) and did not describe the transmission seasonality of the viral infections. Thus, our study is the first to fully describe the epidemiology and viral etiology of ILI in Venezuela and provides baseline levels of ILI activity in a typical highly-populated urban city.

Our study demonstrated that influenza viruses are a main cause of ILI at HCM and IVSS in Maracay in agreement with findings reported by Venezuelas NESS [17–21]. Nevertheless, the rate of confirmed influenza virus infections found in our surveillance (10.6%, 97/916; Table 2 and 3) during the study period was lower than the one (27.7%) reported by the NESS for the same period [17–21]. These differences in detection rates may be attributable to different strategies for capturing ARI patients, especially those with influenza, used by the NESS and by this study protocol (Flores E, Director of Epidemiology, Corposalud 2011, personal communication). The NESS randomly selected a sample of ARI cases (including those with influenza) with emphasis on severe hospitalized cases, whereas in our protocol we recruited ILI subjects in an outpatient setting where the majority had symptoms that were not severe. On the other hand, the percentage of influenza viruses (not including pH1N1) detected in our study during a similar period of time, but in different years (February 2007–July 2008: 22 of 38, 57.9%; data not shown), was much higher than the one reported by Valero et al. (February 2005–July 2006: 7 of 46, 15.2%) [22]. Two causes may have

---

**Table 2. Age distribution of febrile respiratory viral infections detected by passive surveillance in two Hospitals of Maracay, Venezuela: October 2006–December 2010.**

| Age group (in years) | 0–4 | 5–14 | 15–29 | 30–44 | 45–59 | ≥60 | Total |
|---------------------|-----|------|-------|-------|-------|-----|-------|
| **Viral Pathogen**  |     |      |       |       |       |     |       |
| Adenovirus          | 9 (5.6) | 3 (1.2) | 0 | 2 (1.3) | 1 (2.3) | 0 | 15 (1.6) |
| Influenza virus A:  |     |      |       |       |       |     |       |
| H3†                 | 9 (5.6) | 8 (3.2) | 7 (2.3) | 8 (5.1) | 0 | 1 (14.3) | 33 (3.6) |
| H1‡                 | 3 (1.9) | 2 (0.8) | 1 (0.3) | 0 | 0 | 0 | 6 (0.7) |
| Seasonal not subtyped | 3 (1.9) | 2 (0.8) | 4 (1.3) | 1 (0.6) | 1 (2.3) | 0 | 11 (1.2) |
| pH1N1               | 2 (1.2) | 3 (1.2) | 13 (4.3) | 3 (1.9) | 0 | 0 | 21 (2.3) |
| Not subtyped        | 1 (0.6) | 2 (0.8) | 4 (1.3) | 0 | 0 | 0 | 7 (0.8) |
| Influenza virus B   | 4 (2.5) | 10 (4.0) | 5 (1.7) | 0 | 0 | 0 | 19 (2.1) |
| Parainfluenza virus | 6 (3.7) | 1 (0.4) | 3 (1.0) | 3 (1.9) | 0 | 0 | 13 (1.4) |
| RSV*                | 8 (5.0) | 0 | 1 (0.3) | 2 (1.3) | 0 | 0 | 11 (1.2) |
| ORV**               | 2 (1.2) | 2 (0.8) | 0 | 3 (1.9) | 0 | 0 | 7 (0.8) |
| **Positives**       | 47 (29.2) | 33 (13.3) | 38 (12.7) | 22 (14.1) | 2 (4.7) | 1 (14.3) | 143 (15.6) |
| **Negatives**       | 114 (70.9) | 216 (86.7) | 262 (87.3) | 134 (85.9) | 41 (95.3) | 6 (85.7) | 773 (84.4) |
| **Total**           | 161 | 249 | 300 | 156 | 43 | 7 | 916 |

*One mixed infection with herpes simplex virus in a 22 month old toddler.
†Influenza A/H3 subtype.
‡Influenza A/H1 subtype (non-pandemic).
Pandemic (H1N1) 2009 influenza virus.
§Influenza A isolated but not subtyped by RT-PCR (unknown subtype).
Respiratory syncytial virus.
**ORV: Other respiratory viruses, which includes human metapneumovirus, human bocavirus, herpes simplex virus, and enterovirus.

The clinical features of subjects in our surveillance are summarized in Table 3. Compared with those whose respiratory secretions tested negative, subjects in which virus was identified were more likely to have sore throat, headache, pharyngeal congestion, and ear pain. There were no significant differences in the symptoms of individuals who had seasonal influenza A when compared with those who suffered from pH1N1 influenza, except that a higher proportion of the latter subjects had expectoration, myalgias, and lymphadenopathy. The symptoms of influenza A (either seasonal or pandemic) and influenza B were clinically indistinguishable. When compared with patients who had ILI due to other viruses, a higher percentage of those with confirmed influenza virus infection experienced sore throat, myalgias, and headache.
accounted for the significant differences found in both studies: a) the collection, preservation and further processing of respiratory samples, and b) the type of cells and IFA reagents used for virus isolation and identification.

The proportion of influenza cases was significantly different when comparing non-pandemic and pandemic periods. Before the H1N1 2009 pandemic, the NESS [21] detected influenza virus in 64.7% of subjects in whom a virus was isolated; a similar proportion to the 55% (data not shown) found in our study. During the height of the pandemic (from July through Dec 2009), the NESS confirmed 97% of all ARI cases with a virus as having either influenza A or B virus compared with 87% observed in our study.

The predominance of influenza viruses as etiological agents of ILI in Maracay, Venezuela, is consistent with observations of surveillance studies in other tropical Central and South American countries [13,15,16]. While the overall virus detection rate (143/916, 15.6%; Table 2) was lower compared with other studies, the positive rates for influenza A (8.5%) and influenza B (2.1%) in this surveillance were comparable to those observed in a similar study in El Salvador, Honduras, and Nicaragua [16]. Our findings were also consistent with a study in Indonesia, which identified influenza A or B in 11% of all respiratory samples using viral isolation and RT-PCR [25]. Our findings were consistent with those from a prospective study of outpatient children in northern Taiwan, in which influenza A or B were isolated in 12.2% of subjects with ILI, using Madin-Darby canine kidney (MDCK) cell cultures and hemagglutinin inhibition assay for antigen detection [26]. However, our detection rate for all respiratory viruses, as well as influenza A and B viruses, was generally lower compared to other studies conducted in South America. In an expanded sentinel surveillance study in Peru, which utilized a similar methodology for viral detection as our study, the virus positivity rate was 42.1%, and influenza A and B rates were 25.1% and 9.7%, respectively [13]. In a prospective surveillance study of ILI in two Ecuadorian cities using similar methods, at least one virus was detected in 35% of the participants; influenza A was detected by PCR in 21.6% while 6.4% tested positive for influenza B [15]. The lower virus detection rates found in our study is unclear because we used the same operative protocol described in the mentioned studies [13,15]. Nevertheless, the different skills to collect respiratory tract specimens from ILI patients, by the health personnel employed in their studies and ours may have accounted for the lower virus detection rates found in our study.

While influenza viruses were observed to be the most prevalent viral pathogen, adenovirus, parainfluenza virus, and RSV were
important causes of ILI at the two hospitals (Table 2). In Venezuela, the NESS reported RSV as the most frequently detected non-influenza respiratory virus followed by parainfluenza virus and rhinovirus [17–21]. The study performed in Zulia, Venezuela, also reported RSV as the most common detected virus, followed by adenovirus, parainfluenza virus and influenza viruses [22]. As previously mentioned, the differences in the detection rates may be attributed to the different procedures used by the NESS, other Venezuelan researchers [22] and us. These viral pathogens were also frequently detected in other surveillance studies in Central and South America [14–16].

The highest detection rate of respiratory viruses was observed in the 0–4 year old group (29.2%; Table 2). The rate of viral positivity generally decreased with age as acquired immunity increased in older subjects. A slight increase can be seen between the 30–44 year old group (14.1%) and 60 years or older group (14.3%). Subjects who were 60 years old or older comprised less than 1% of the study population, and thus, the prevalence in this age group may be unreliable. Contrary to our study, the other study from Venezuela had higher detection rates in both the 0–6 and ≥11 year old groups (48.2% and 57.1%, respectively) [22]. On the other hand, our findings are consistent with observations in the Tecumseh Study, a community-based surveillance in Michigan, in which children were shown to have the highest rate of viral respiratory diseases [5,6]. The Tecumseh study further illustrated the variable impact of influenza viruses among the different age groups depending on the influenza virus subtype. For example, influenza A/H3N2 affected a wide range of age groups while influenza A/H1N1 and influenza B virus infections occurred more frequently among older children and young adults [5,6]. Our findings were similar being seasonal influenza A/H1N1 viruses and influenza B detected primarily in children and young adults, and seasonal influenza A/H3N2 found in all age groups.

As expected, pH1N1 was the most common influenza A subtype identified among the subjects with ILI in 2009 (Figure 3). In 2009, 37.5% (Figure 3) of ILI cases were due to pH1N1; this detection rate was lower than the 52.2% detection rate reported by the Venezuela’s NESS [21]. Nevertheless, this finding was similarly demonstrated in respiratory illness surveillance networks in other tropical and temperate South American countries such as Guatemala [27], Peru [28], Argentina [29], and Brazil [30]. In 2010, non-pandemic influenza viruses continued to circulate in Venezuela, and pH1N1 was not detected in our surveillance study, suggesting that pH1N1 did not displace seasonal influenza A viruses. During the same year, 1.6% of the ARI cases reported to Venezuela’s NESS were due to pH1N1 [21]. Infection with pH1N1 may have stimulated immunity among the residents of this community during its initial arrival in 2009. This observation suggests that the circulating pH1N1 in 2010 may not have significantly mutated relative to the strain in 2009, so that antibodies stimulated by the natural infection during its initial arrival may have still been highly efficient in protecting the
community from another wave of pH1N1 outbreak. In 2010, the infection rate of influenza A/H3 was higher than the rates observed during previous years, further illustrating the lack of cross protection between pH1N1 and influenza A/H3.

Our study shows that hMPV and HBoV were not commonly associated with ILI, based on the low detection rates observed in our surveillance. In a study from Ecuador which utilized methods similar to those employed in our study, a low detection rate for HBoV (0.2%) was reported [15]. The latter study, as well as another from Central America which used methods similar to ours, reported rare detection of hMPV (<0.2%) [15,16]. In contrast, a prospective study of ILI among Brazilian adults which utilized viral isolation and RT-PCR testing on respiratory samples, detected rhinoviruses in 19.6% of patients [14]. Although rhinoviruses are typically associated with milder illness, they can contribute to the misdiagnosis of influenza based on clinical case definition alone. A cohort study of Vietnamese children hospitalized for acute febrile respiratory illness, which applied multiplex-PCR assays on respiratory samples, revealed slightly higher prevalence rates of HBoV (2%) and hMPV (5%) infections [31]. It is important to note that our method of identification (culture on three cell lines), compared to molecular diagnostic methods, substantially lacked sensitivity for detecting rhinoviruses, hMPVs, and HBoVs.

Our study shows that patients with pH1N1 infections were more likely to have myalgias, productive cough with expectoration, and lymphadenopathy than with those infected with seasonal influenza A virus (Table 3). In contrast, clinical manifestations in Guatemalan subjects hospitalized for pH1N1 and seasonal influenza A infections did not significantly differ [27].

Our study had limitations worth noting. Data collection at only two hospitals in an urban area limits our ability to generalize our findings to the population. The low virus detection rates may be attributable to variations in the skills of the health staff employed to collect the respiratory specimens. The sampling method may have a significant effect on the proportion of respiratory viruses identified, and nasopharyngeal washes may yield higher sensitivity over nasopharyngeal or oropharyngeal swabs [32]. Study participants were exclusively seen in the outpatient setting, thus limiting our ability to examine the impact of respiratory viruses in hospitalized cases. A large proportion of ILI cases were not associated with any pathogen, and the impact of bacteria on this clinical syndrome cannot be determined from this study, since the respiratory samples were not cultured for bacteria. Two methods of detection were used for identification of influenza (PCR and culture) whereas only one method of detection was used for the other viruses (culture). Twenty-two percent (9/40) of the respiratory samples which were positive for influenza viruses by RT-PCR were negative by viral isolation illustrating that viral detection by culture underestimated the true prevalence. Viral culture may not be the ideal way of isolating organisms such as RSV, hMPV, HBoV and rhinoviruses leading to significant underestimation of their detection rates [33].

### Table 3. Signs and symptoms of patients with acute febrile respiratory infections detected by virus identified in two health centers of Maracay, Venezuela: October 2006–December 2010.

| Signs/Symptoms            | Total No. (%) | No Virus Detected N = 916 | Virus Detected N = 773 | No. (%) | Seasonal Influenza A N = 143 | No. (%) | Influenza B N = 50 | No. (%) | pH1N1 N = 21 | No (%) | Other viruses** N = 46 |
|---------------------------|---------------|---------------------------|------------------------|---------|----------------------------|---------|-------------------|---------|-------------|--------|----------------------|
| Cough                     | 880 (96.1)    | 749 (96.9)                | 131 (91.6)             | 46 (92.0) | 18 (94.7)                 | 20 (95.2) | 40 (87.0)        |
| Malaise                   | 864 (94.3)    | 730 (94.4)                | 134 (93.7)             | 45 (90.0) | 18 (94.7)                 | 21 (100.0) | 43 (93.5)        |
| Rhinorrhea                | 861 (94.0)    | 729 (94.3)                | 132 (92.3)             | 48 (96.0) | 16 (84.2)                 | 17 (81.0) | 42 (91.3)        |
| Sore throat               | 178 (19.4)    | 135 (17.5)                | 43 (30.1)*             | 21 (42.0) | 4 (21.1)                  | 9 (42.9)   | 8 (17.4)*         |
| Expectoration             | 536 (58.5)    | 459 (59.4)                | 77 (53.8)              | 23 (46.0) | 7 (36.8)                  | 18 (85.7)† | 23 (50.0)        |
| Myalgias                  | 499 (54.5)    | 433 (56.0)*               | 66 (46.2)              | 20 (40.0) | 8 (42.1)                  | 16 (76.2)† | 15 (32.6)‡        |
| Headache                  | 388 (42.4)    | 309 (40.0)                | 79 (55.2)*             | 30 (60.0) | 9 (47.4)                  | 15 (71.4)  | 19 (41.3)‡        |
| Wheezing                  | 342 (37.3)    | 310 (40.1)*               | 32 (22.4)              | 9 (18.0)  | 6 (31.6)                  | 3 (14.3)   | 14 (30.4)        |
| Shortness of breath       | 267 (29.1)    | 224 (29.0)                | 43 (30.1)              | 12 (24.0) | 9 (47.4)                  | 9 (42.9)   | 12 (26.1)        |
| Pharyngeal congestion     | 132 (14.4)    | 81 (10.5)                 | 51 (35.7)*             | 21 (42.0) | 4 (21.1)                  | 6 (28.6)   | 15 (32.6)        |
| Asthenia                  | 71 (7.8)      | 59 (7.6)                  | 12 (8.4)               | 3 (6.0)   | 3 (15.8)                  | 2 (9.5)    | 2 (4.4)          |
| Ear pain                  | 55 (6.0)      | 37 (4.8)                  | 18 (12.6)*             | 8 (16.0)  | 0                         | 2 (9.5)    | 3 (6.5)          |
| Diarrhea                  | 53 (5.8)      | 44 (5.7)                  | 9 (6.3)                | 2 (4.0)   | 1 (5.3)                   | 2 (9.5)    | 3 (6.5)          |
| Conjunctival injection    | 36 (3.9)      | 18 (2.3)                  | 18 (12.6)              | 7 (14.0)  | 2 (10.5)                  | 2 (9.5)    | 5 (10.9)         |
| Lymphadenopathy           | 18 (2.0)      | 12 (1.6)                  | 6 (4.2)                | 0         | 0                         | 3 (14.3)†  | 1 (2.2)          |
| Abdominal pain            | 14 (1.5)      | 9 (1.2)                   | 5 (3.5)                | 3 (6.0)   | 0                         | 2 (9.5)    | 0               |

*Statistically significant differences (p<0.05) between patients with ILI – due to influenza viruses and ILI – due to viruses other than influenza viruses.

†Statistically significant differences (p<0.05) between patients with seasonal influenza A and pH1N1.

‡Statistically significant differences (p<0.05) between patients with ILI in whom virus was detected vs. virus was not detected.

**Other viruses: human metapneumovirus, human bocavirus, herpes simplex virus, respiratory syncytial virus, adenovirus, parainfluenza virus, and enterovirus.

doi:10.1371/journal.pone.0044511.t003
Materials and Methods

Study Sites
Maracay is located in the central northern region of Venezuela (10° 15’ N, 67° 39’ W), approximately 27 miles from the Caribbean coast (Figure 4). The climate is tropical with two seasons: dry (December–April) and rainy (May–November). The monthly averages for temperature, relative humidity and rainfall are 25.1°C (range = 23.4°C–27.6°C), 75% (range = 66%–82%) and 56 mm (range: 0 mm–187 mm), respectively. Maracay is comprised of two main urban municipalities, named Girardot and Mario Briceño Iragorry, and had an estimated total population of 677,359 in 2010. The HCM and the IVSS-JMCT are located approximately 4 miles apart. Both are major county hospitals and referral health centers with adult and pediatric departments including emergency services and 241 (IVSS-JMCT) to 433 (HCM) hospitalization beds. They provide services to people in Maracay as well as those from the adjacent city of Aragua and three neighboring states.

Study Population
The study population included every outpatient with ILI, regardless of age, who sought attention at the two study sites between October 2006 and December 2010, and agreed to participate in the study. At each site, trained medical personnel were responsible for properly identifying and classifying patients with ILI.

Case Definition
Each person with ILI was asked to enroll in the study. A person was defined as having ILI if he or she had a sudden onset of fever (≥38°C) and either cough or sore throat for less than five days in duration, with or without general symptoms such as myalgias, prostration, headache, or malaise [13].

Data Collection and Management
Data on gender, age, previous treatments, medical attention before enrollment, influenza vaccination status, and days of work/school lost at the time of acute illness were collected utilizing a case report form (CRF) from all participants who met the case definition criteria. Temporal distribution of the results were recorded by month during the study period, taking into account the number of ILI cases identified and the number of confirmed cases of influenza A and B in each study site. Monthly reports of enrolled ILI participants and laboratory results were sent to the Venezuelan Ministry of Health. Regular personnel training in protocol procedures were conducted as part of the strategy to improve sampling, storage, and shipping procedures.

Ethical Management
This protocol was approved as less than minimal risk research by the Naval Medical Research Center (NMRC), Silver Spring, Maryland. Institutional Review Board (IRB; Protocol NMRCD.2002.0019) authorization was given to perform the study using an information sheet approved and stamped by the IRB. As this was part of clinical care and routine surveillance.

Figure 4. Map of study sites in Venezuela.
doi:10.1371/journal.pone.0044511.g004
benefiting the ministry of health, verbal consent was obtained from all participants. This method of consent was accepted by the NMRC IRB as well as the Venezuelan institutions involved. A verbal consent was approved by both IRBs following CIOMS and 45CFR46 (the Common Rule), 1) it was a minimal risk study, and 2) local health installations would not require a written consent for the procedures required in this study. Additionally, this document included all the information that a written consent would require; a copy was provided to each study subject; and study personnel responsible for administering the process of informed consent were trained at each site on human research protection issues and were certified through the Collaborative Institutional Training Initiative (CITI). Finally, the frequent monitoring visits conducted by the study team found no problems in the process nor complaints from study participants.

**Laboratory Analysis**

**Sample collection.** Nasal (807 of 916, 88.1%) or oropharyngeal (109 of 916, 11.9%) swabs were obtained from each subject for viral isolation and identification. The swabs were placed in viral transport media and stored at –70°C until they were delivered on dry ice to NAMRU-6 in Lima, Peru, for laboratory analysis. Duplicate swabs were processed and analyzed at the Laboratorio Regional de Diagnostico e Investigacion del Dengue y otras Enfermedades Virales/Instituto de Investigaciones Biometricas de la Universidad de Carabobo (LARDIDEV/BIOMED-UC) in Maracay, Venezuela, following the same operative protocols used in NAMRU-6.

**Virus isolation and identification.** Nine-hundred and sixteen nasal or oropharyngeal swabs were processed for viral isolation and identification following the procedure described by Laguna-Torres et al. [13]. Briefly, patient specimens were inoculated onto four cell lines: Madin-Darby canine kidney (MDCK; ATCC® Number CCL-34), African green monkey kidney (Vero76; ATCC® Number CRL-1587) and VeroE6 ATCC® Number CRL-1586, and Rhesus monkey kidney (LLC-MK2 ATCC® Number CCL-7). Upon the appearance of cytopathic effect or after ten days of culture (or thirteen days in the case of Vero cells), the cells were spotted onto microscope slides. Cell suspensions were dried and fixed in chilled acetone for 15 minutes. Virus isolates were identified using direct fluorescence antibody (DFA) assays. The Respiratory Virus Screening and Identification Kit (D3 DFA Respiratory Virus Diagnostic Hybrids; Athens, OH) was utilized for the identification of adenoviruses, influenza A virus, influenza B virus, parainfluenza viruses (types 1, 2, and 3), and RSV. The D3 DFA Herpes Simplex Virus (HSV) identification kit and the D3 IFA Enterovirus ID kit (Diagnostic Hybrids; Athens, OH) were utilized for the identification of HSV (both HSV-1 and HSV-2) and enteroviruses, respectively. For isolation of hMPV, we used Vero E6 and LLC-MK2 cell lines. For detection of hMPV antigens by direct fluorescence assay, we used an anti-hMPV mouse monoclonal antibody from Diagnostic and/or Real Time RT-PCR were not used to identify non-influenza viruses because the specific primers and protocols were available only for sub-typing influenza viruses; thus, only virus isolation was used to detect and identify non-influenza viruses. Of the 254 specimens, 40 (15.9%) were randomly selected from repository samples collected before the 2009 pandemic and tested for influenza A sub-typing by one-step RT-PCR and/or Real Time RT-PCR. At the onset of the 2009 pandemic, 150 of 254 (59.1%) respiratory samples were tested for pH1N1 by Real Time RT-PCR at the request of the Venezuelan Ministry of Health. After the peak of the second wave of the pandemic, the percentage of respiratory samples tested by Real Time RT-PCR was reduced to 22% (56 of 254).

One-step RT-PCR was performed according the procedure and influenza primers described below, Real Time RT-PCR was carried out using procedures (CDC protocols CDC REF. # I-007-05 Version 2007, CDC REF. # LB-013, R-1 and CDC REF. # I-007-05 Version 2009: Swine Influenza) and materials provided by the Influenza Division of the Centers for Disease Control and Prevention, U.S.A. (Stephen Lindstrom, personal communication). These protocols are available from CDC upon request. For the purpose of this study, an ILI case with a confirmed viral respiratory infection was one in which viral isolation and/or RT-PCR identified a virus.

**RNA extraction and one-step RT-PCR.** Viral RNA extraction was performed from the supernatant of infected MDCK cells using a QIAamp Viral RNA kit (QIAGEN; Valencia, CA) following the manufacturer’s protocol. The one-step RT-PCR was performed following a procedure described previously [13] with primers that amplified the hemagglutinin (HA) gene of influenza A and influenza B viruses using the SuperScript III One-Step RT-PCR System kit (Invitrogen; San Diego, CA). The following primers were used for the amplification of H1 influenza A viruses: H1F-6 (5’-AAGCAGGGGAAAATAAAAA-3’); H1R-1193 (5’-GTAATCCGGTTAATTGGCA-3’); for H3 influenza A viruses: H3F-7 (5’-ACTAT-CATTGCTTTGACC-3’); and H3R-1184 (5’-ATGGCTGCTTGAGTTACTTT-3’); for influenza B viruses: BHAF-36 (5’-GAAGGCACATATTGTACT-3’), and BHAR-1140 (5’-ACCCAGAATAGCTCGGAA-3’). Five μl of the extracted RNA was added to 20 μl of master mix containing the enzyme mixture (SuperScript III RT/Platinum Taq), 2X reaction mixture (containing 0.4 mM of each dNTP and 3.2 mM of MgSO4) and 20 μM of each primer. Cycling conditions included a reverse transcription step at 50°C for 30 minutes and a denaturation step at 94°C for 2 minutes. Cycling conditions of the PCR were 40 cycles of 94°C for 15 seconds, 52°C for 30 seconds, and 68°C for 75 seconds, followed by a final incubation step at 68°C for 5 minutes.

**DNA sequencing and phylogenetic analysis.** For confirmation of serotype and genotype of the circulating influenza viruses, 27 samples were sequenced. As part of the Respiratory Surveillance Protocol in Venezuela, these 27 viruses were randomly selected from approximately 10% of the positive samples. Only the HA gene region of influenza viruses was analyzed routinely for genotyping. The one-RT-PCR products amplified with the primers described before were purified using Centri-Sep Columns (Princeton Separation; Englishtown, NJ) and sequenced using the BigDye Terminator v. 3.1 Cycle Sequencing Kit (Applied Biosystems; Foster City, CA) following the manufacturers’ instructions. Sequences were analyzed and edited using the Sequencer 4.8 software (Applied Biosystems; Foster City, CA).

Phylogenetic trees were constructed by the neighbor-joining method and bootstrap analysis to determine the best-fitting tree for...
the gene using MEGA software (version 4). The statistical significance of the tree topology was tested by bootstrapping (1,000 replications). Pairwise distances between and within the genotypes at the nucleotide level were calculated with Kimura 2 parameters and with Poisson correction at the amino acid level with MEGA software. Genbank accession numbers are listed in Table S1.

Statistical Analysis
Information on the CRFs was entered into a database created in Microsoft Office Access 2003. The chi square and Fisher exact tests were used to compare means and associations using SPSS software version 10.0 (SPSS Inc.; Chicago, IL) and R version 2.8.0 (R Development Core Team; Vienna, Austria).

Supporting Information
Table S1 Genbank accession numbers of DNA sequences from 27 Influenza viruses isolated in two health centers of Maracay, Venezuela: October 2006–December 2010.

Acknowledgments
We would like to express our gratitude to all personnel working at the two sentinel health centers (HCM and IVSS-HJMCT) in Venezuela for supporting this surveillance study. We thank Mr. Eduardo Guerra, the Informatics Superior Technician of LARDIDEV/BIOMED-UC, for his irreplaceable technical work in Venezuela. We also thank the professional staff of the Virology Department of NAMRU-6 for invaluable laboratory and technical support in the execution of the study.

Disclaimer: The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, Department of Defense, nor the U.S. Government. The corresponding author had full access to all data in the study and final responsibility for the decision to submit this publication.

Additional Copyright Statement: Ninfa Teneza-Mora, Tadeusz J. Kochel, and Eric S. Halsey are U.S. military service members, and V. Alberto Laguna, Josefina Garcia, Gloria Chauca, Maria E. Gamoero, and Merly Sovero are employees of the U.S. Government. This work was prepared as part of their official duties. Title 17 U.S.C. § 105 provides that “Copyright protection under this title is not available for any work of the United States Government.” Title 17 U.S.C. § 101 defines a U.S. Government work as a work prepared by a military service member or employees of the U.S. Government as part of those persons’ official duties.

Author Contributions
Conceived and designed the experiments: G. Comach TJK VALT. Performed the experiments: DEC G. Chauca MEG MS. Analyzed the data: G. Comach NTM TJK CE GS DEC VALT. Wrote the paper: G. Comach TJK GS DEC G. Chauca MEG MS SB IV AM. Revised the article critically for important intellectual content: TJK CE GS DEC VALT JG ESH.

References
1. Mathers CD, Loncar D (2006) Projections of global mortality and burden of disease from 2002 to 2050. PLoS Med 3: 2012–2030.
2. Denn F, Loza FA (1986) Acute respiratory infections are the leading cause of death in children in developing countries. Am J Trop Med Hyg 35: 1–2.
3. WHO (2008) The global burden of disease: 2004 update. Available: http://www.who.int/healthinfo/global_burden_disease/2004_report_update/en/. Accessed 2011 Oct 1.
4. Monto AS (2004) Occurrence of respiratory virus: time, place and person. Pediatr Infect Dis J 23: 538–546.
5. Monto AS (1995) Viral respiratory infections in the community: Epidemiology, agents, and interventions. Am J Med 99: 24s–27s.
6. Monto AS, Najjar JA, Metzner HL (1971) The Tecumseh study of respiratory illness. Am J Epidemiol 94: 269–289.
7. Monto AS (2002) Epidemiology of viral respiratory infections. Am J Med 112: 4s–12s.
8. Lambert SB, Allen KM, Druce JD, Birch CJ, Mackay IM, et al. (2007) Community epidemiology of human metapneumovirus, human coronavirus NL63, and other respiratory viruses in healthy preschool-aged children using parent-collected specimens. Pediatrics 120: e929–e937. Available: http://pediatrics.aappublications.org/content/120/4/e929.full.pdf+html. Accessed 2011 October 1.
9. Ruuskonen O, Lahni E, Jennings LC, Murdoch DR (2011) Viral pneumonia. Lancet 377(9767): 1264–1275.
10. Thompson WW, Shy DK, Weintraub E, Brammer I, Bridges CB, et al. (2004) Influenza-associated hospitalizations in the United States. JAMA 292: 1333–1340.
11. Thompson WW, Shy DK, Weintraub E, Brammer I, Cox N, et al. (2003) Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 290: 179–186.
12. CDC (2010) Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 59: 1–62. Available: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5901a1.htm. Accessed 2010 Oct 1.
13. Lagunas-Torres VA, Gomez J, Ocaña V, Aguilar P, Saltarria I, et al. (2009) Influenza-like illness sentinel surveillance in Peru. PLoS One 4(7): e6116.
14. Beilii N, Carrero E, Persoa A, Watanabe A, Arruda E, et al. (2008) Acute respiratory infection and influenza-like illness viral etiologies in Brazilian adults. J Med Virol 80: 1024–1027.
15. Douc RE, Aleman W, Chicaiza-Ayala W, Madril C, Sovero M, et al. (2011) Sentinel surveillance of influenza-like illness in two cities of the tropical country of Ecuador: 2006–2010. PLoS One 6: 1–13.
16. Lagunas-Torres VA, Sanchez-Largoespada JJ, Lorenzoza I, Forshey R, Aguilar P, et al. (2010) Influenza and other respiratory viruses in three Central American countries. Influenza Other Respi Viruses 5: 123–134.
17. Ministerio del Poder Popular para la Salud (2010) Boletín epidemiológico semanal epidemiología 52. Available: http://www.bvs.org.ve/boletin_epidemiologico/2010/Boletin_52_2010.pdf. Accessed 2011 Dec 1.
18. Ministerio del Poder Popular para la Salud (2006) Boletín epidemiológico semanal epidemiología 52. Available: http://www.mpps.gob.ve/option=com_pln&task=download&view=categoryid=5:2006. Accessed 2012 Jul 17.
19. Ministerio del Poder Popular para la Salud (2007) Boletín epidemiológico semanal epidemiología 52. Available: http://www.bvs.org.ve/boletin_epidemiologico/2007/Boletin_Epidemiologico_SE_52_2007.pdf. Accessed 2011 Dec 1.
20. Ministerio del Poder Popular para la Salud (2008) Boletín epidemiológico semanal epidemiología 52. Available: http://www.bvs.org.ve/boletin_epidemiologico/2008/BoletinEpidemiologicoSemana52_2008.pdf. Accessed 2011 Dec 1.
21. Ministerio del Poder Popular para la Salud (2009) Boletín epidemiológico semanal epidemiología 52. Available: http://www.bvs.org.ve/boletin_epidemiologico/2009/boletin_52_2009.pdf. Accessed 2011 Dec 1.
22. Valero N, Larreal Y, Arocha F, Gotera J, Mavares A, et al. (2009) Etiología viral de las infecciones respiratorias agudas. Invest Clin 50(3): 339–368.
23. Sovero M, Garcia J, Lagunas-Torres VA, Gomez J, Aleman W, et al. (2010) Genetic analysis of influenza A/H1N1 of swine origin virus (SOIV) circulating in Central and South America. Am J Trop Med Hyg 83: 708–710.
24. CDC (2009) Outbreak of swine-origin influenza A (H1N1) virus infection – Mexico, March–April 2009. MMWR 58: 467–470. Available: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5823a1.htm. Accessed 2012 Feb 2. (2009) Outbreak of swine-origin influenza A (H1N1) virus infection – Mexico, March–April 2009. MMWR 58: 467–470. Available: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5823a1.htm. Accessed 2012 Feb 2.
25. Beckett CG, Kosaah H, Ma’reef C, Listiyaningsih E, Elyazar IR, et al. (2004) Influenza surveillance in Indonesia: 1999–2003. Clin Infect Dis 39: 443–449. Available: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5901a1.htm. Accessed 2003 Oct 1.
26. Lin TV, Huang YC, Ning HC, Tsao WC (2004) Surveillance of respiratory viral infections among pediatric outpatients in northern Taiwan. J Clin Virol 30: 81–85.
27. Lindblad KA, Arvelo W, Gray J, Estevez A, Frenkel G, et al. (2010) A comparison of the epidemiology and clinical presentation of seasonal influenza A and 2009 pandemic influenza A(H1N1) in Guatemala. PLoS One 5: 1–11.
28. Gomez J, Munayco CV, Arrascós JC, Suarez L, Lagunas-Torres VA, et al. (2009) Pandemic influenza in a southern hemisphere setting: The experience in Peru from May to September, 2009. Eur Surveill 14: 1–6. Available: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19371. Accessed 2001 Oct 1.
29. Echavarria M, Querci M, Morcione D, Videla C, Martinez A, et al. (2010) Pandemic (H1N1) 2009 cases, Buenos Aires, Argentina. Emerg Infect Dis 16(2): 311–313.
30. Schout D, Haijar LA, Galas FR, Up DE, Levin AS, et al. (2009) Epidemiology of human infection with the novel virus influenza A(H1N1) in the Hospital das Clinicas, Sao Paulo, Brazil - June-September 2009. Clinics (Sao Paulo) 64: 1025–1030.
31. Yoshida LM, Suzuki M, Yamamoto T, Nguyen HA, Nguyen CD, et al. (2010) Viral pathogens associated with acute respiratory infections in Central Vietnamese children. Pediatr Infect Dis J 29: 75–77.

32. Lieberman D, Shimoni A, Shemer-Avni Y, Keren-Naor A, Shitainberg R (2010) Respiratory viruses in adults with community-acquired pneumonia. Chest 138: 811–816.

33. Leland DS, Ginocchio CC (2007) Role of cell culture for virus detection in the age of technology. Clin Microbiol Rev 20: 49–78.

34. Salmo´n-Mulanovich G, Sovero M, Laguna-Torres V, Kochel T, Lescano A, et al. (2011) Frequency of human bocavirus (HBoV) infection among children with febrile respiratory symptoms in Argentina, Nicaragua and Peru. Influenza Other Respir Viruses 5: 1–5.